Coexistence of malignant ovarian Brenner tumor and borderline mucinous cystadenoma, combined with primary uterine corpus endometrioid carcinoma: A case report and literature review

CANCAN ZOU1, QIONG LI1*, JINGBO ZHAO2 and YANLIN CHEN1

1Department of Pathology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147; 2Anbiping (Chongqing) Pathological Diagnosis Center, Chongqing 400030, P.R. China

Received March 9, 2022; Accepted May 24, 2022

DOI: 10.3892/ol.2022.13392

Abstract. Malignant Brenner tumor (MBT) of the ovary is a rare malignant ovarian tumor, whereas uterine corpus endometrioid carcinoma (UEC) constitutes one of the most common malignant tumors of the female reproductive system. The present study reported on a case of the coexistence of ovarian MBT and borderline mucinous cystadenoma combined with primary UEC. Therefore, the present case is a synchronous primary cancer of both ovary and endometrium. Although synchronous primary cancers of the endometrium and ovary are relatively uncommon, they are not rare; however, due to the rarity of MBT, this case was considered singular. To the best of our knowledge, this was the first-ever reported case of the coexistence of an ovarian MBT and borderline mucinous cystadenoma combined with primary UEC. Based on a review of the literature associated with the present case, its clinicopathological features, immunohistochemical phenotype, differential diagnosis, molecular changes, prognosis and treatment were summarized and discussed. The aim of the present study was to improve the understanding of this rare synchronous primary cancer of the ovary and endometrium so as to avoid future misdiagnosis.

Introduction

Contemporaneous primary cancers of the endometrium and ovary comprise the most common synchronous gynecologic malignancies; they are detected in 3-5% of all patients with endometrial cancer and in 3-10% of all patients with ovarian cancer (1). Endometrioid endometrial carcinoma (EEC) is the most common histological subtype of synchronous endometrial and ovarian carcinoma, while other comorbidities are rare (2). In addition, the coexistence of ovarian Brenner tumor (BT) and mucinous neoplasm is not uncommon, accounting for ~16% (3). However, to the best of our knowledge, no previous study exists on the coexistence of ovarian malignant (MBT) and borderline mucinous cystadenoma combined with primary uterine corpus endometrioid carcinoma (UEC). Therefore, the present study reported on this current rare case of synchronous primary ovarian MBT with borderline mucinous cystadenoma complicated with primary UEC encountered at our hospital. Furthermore, a literature review was performed and the overall clinicopathologic features, immunohistochemical phenotypes, differential diagnosis, molecular changes and the prognosis and treatment of the disease were summarized. The purpose of this case report was to alert clinicians and pathologists that they may encounter similar cases in clinical practice. In order to reach an accurate pathologic diagnosis of this type of synchronous endometrial-ovarian primary cancer, it is recommended that the pathologist aggregates and closely examines the patient's clinical history, imaging data, morphologic characteristics and immunohistochemical and molecular testing results, and ultimately performs a comprehensive analysis.

Case report

Case presentation. A 50-year-old female patient presented at the Women and Children’s Hospital of Chongqing Medical University (Chongqing, China) in May 2021 with an eight-month history of abnormal uterine bleeding, lower-abdominal-distension pain with lumbar pain and swelling for three months, as well as increased vaginal discharge for four days. The patient had been physically healthy in the past and medical history was unremarkable. Tumor-marker levels were as follows: CA19-9, >12,000.00 U/ml; CA-125, 256.3 U/ml; and CEA, 19.7 ng/ml. Magnetic resonance imaging of the abdomen and pelvis indicated that the uterine cavity was dilated and exhibited a lumpy mass with slightly long T1 and T2 signals. The mass size was ~8.4x3.5 cm, with slight enhancement upon

Correspondence to: Dr Yanlin Chen, Department of Pathology, Women and Children's Hospital of Chongqing Medical University, 120 Longshan Street, Yubei, Chongqing 401147, P.R. China
E-mail: chenyl_doctor@163.com

*Contributed equally

Key words: malignant Brenner tumor of the ovary, borderline mucinous cystadenoma, primary endometrioid carcinoma, synchronous primary cancer, literature review
enhanced-scan imaging. Multilocular cystic-solid occupying masses were uncovered in both left and right appendages, with sizes of 6.2x3.2x5.7 and 15.1x15.2x9.1 cm, respectively. The solid portion of the masses was located in their lower aspects and protruded into the respective cavity in papillary- and cauliflower-like shapes. Enhanced scanning indicated that the solid components, capsule wall and septum were also significantly enhanced. Hysteroscopy indicated that the uterine cavity was filled with abnormal endometrium with fragile tissue structures and a large number of abnormal blood vessels were also observed in the endometrium, with the neoplasm having invaded the cervical canal. Curettage was performed under hysteroscopy and the specimen was sent for pathologic examination. Microscopically, the atypical endometrioid glands fused with each other in the tissues collected from the cervix and uterine cavity, and the cancer cell atypia ranged from mild to moderate, with pathologic mitoses noted. The pathologic diagnosis based on cervical and uterine cavity curettage was endometrioid carcinoma [Federation of Gynecology and Obstetrics (FIGO) grade I]. Due to the pathological diagnosis and imaging anomalies, the patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and bilateral pelvic lymph node dissection.

Gross specimen characteristics. The samples included the whole uterus, bilateral adnexa, parauterine tissue and resected lymph nodes. In the left adnexa (Fig. 1), a cystic-solid mass of 9.0x8.0x4.5 cm with a smooth surface was noted; the mass had been cut open and the cystic content was lost. The wall thickness of the cyst was 0.2-0.5 cm and the size of the solid component was 5.0x3.0x3.0 cm. The cut surface of the solid portion was gray-white, adhesive and delicate in texture. A fallopian tube with a length of 6.0 cm and a diameter of 1.0 cm was attached to the surface of the mass and no oviductal umbrella was observed. A cystic-solid mass of 12.0x8.0x4.0 cm in size in the right adnexa was also noted; the mass had been incised and the cavity's content was also missing. The wall thickness of the cystic component was 0.2-0.5 cm and the size of the solid component was ~9.0x6.0x3.0 cm. The cut surface of the solid portion was gray-white, adhesive and soft and delicate in texture, and the papilla protruded into the cyst. The uterine cavity was filled with grayish-white and fragile tumorous tissue and the endometrium was diffusely thickened to ~0.5-1.0 cm. The tumors infiltrated half-way into the muscle wall layer and extended into the cervical canal. The section of the cervical canal wall included a 2.0x1.8x1.5 cm grayish-white mass of medium texture and unclear boundary and a biopsy was taken. Besides, the serosa of the cervix was slightly coarse (Fig. 2A).

Microscopic characteristics on pathologic examination. No normal ovarian tissue was found in the left and right adnexa. In the cystic area, the cystic wall was lined with mucinous epithelium and goblet cells were observed (magnification, x100) (Fig. 3A). Over 10% of the mucous epithelium of the cyst wall was stratified and part of the epithelium was fused into a papillary or cribriform structure (Fig. 3B). Cell atypia ranged from mild to moderate and mitotic figures were clearly recognizable. Fig. 3C indicates the coexistence of mucous epithelium with the urothelium, while Fig. 3D displays a typical urothelial tumor area. The tumor cells exhibited nest-like infiltration in the solid area of the mass. Certain nests had a central glandular cavity that was lined with mucous epithelium that contained eosinophilic mucus or that exhibited necrosis (Fig. 3E). In the poorly differentiated area, the tumor cells infiltrated into the stroma with cord-like, trabecular and gland-like structures (Fig. 3F), and they had moderate to severe atypia. The shape of the nuclei was round, oval, irregular or vacuolar, with smudged chromatin and obvious nucleoli. The cytoplasm was clear or eosinophilic
and pathologic mitoses were readily observed (magnification, x400) (Fig. 3G). Necrosis, squamous cell metaplasia and psammoma bodies were also observed (Fig. 3H). The mass from the uterine endometrium exhibited well-differentiated EEC that infiltrated the uterine myometrium to <1/2 the muscle layer (Fig. 2B), and the cervical wall was invaded to a depth of ~2/3 the layer. A proportion of the carcinomatous tissues featured microcystic, elongated and fragmented (MELF)
myometrial invasion (Fig. 2C). It is important to note that the histomorphologic appearance of the mass on the cut surface of the cervical canal wall was identical to that of the adnexal mass (Fig. 2D) and the serosal surface was also infiltrated by the tumor. Although the right parauterine tissue and one lymph node from 15 resected right pelvic lymph nodes exhibited MBT metastasis, no tumor metastasis was detected in the resected lymph nodes from other regions.

**Immunohistochemical findings.** The immunohistochemical findings are summarized in Table I. Components of the MBT from the left and right adnexa (Fig. 4) were positive for the epithelial markers cytokeratin (CK), epithelial membrane antigen (EMA) and CK7, and for the urothelial marker Uroplakin III (UP-III). Tissues stained positive for steroidogenic factor 1 and weakly positive for p63, positive for CEA in a portion of the tumor, and positive for the molecular genetics-related proteins MDM2, C-myC, cyclin D1 and EGFR. The Ki67 hotspot index with respect to tumor cells was ~70% and tissues were negative for estrogen receptor (ER) and progesterone receptor (PR). Tissues were unreactive toward P16, P53 protein expression was wild-type, and they were negative for the Mullerian duct markers paired box 2 (Pax-2), Pax-8 and germ cell source marker spalt-like transcription factor 4 (SALL4), as well as for the gastrointestinal markers stablin-2, CK20, caudal type homeobox 2; WT-1, Wilms' tumor protein-1; VIM, vimentin; UP-III, uroplakin III; MUC2, mucin 2; ER, estrogen receptor; PR, progesterone receptor.

Regarding UEC components, ER, PR and vimentin antibodies reacted positively; furthermore, CK7 was positive with CEA being locally positive. In contradistinction, P16 and Wilms' tumor protein-1 (WT-1) markers were negative and P53 protein exhibited wild-type expression. The mismatch repair gene-related proteins MutL homolog 1 (MLH1), postmeiotic segregation increased 2 (PMS2), mutS homolog 2 (MSH2) and MSH6 were positive.

**Pathologic diagnosis.** The following observations were considered in the diagnosis: i) Bilateral ovaries: MBT with borderline mucinous tumor, invasion of uterine serosal surface, and cervical stroma and infiltration of vessels; ii) UEC grade I, invasion of...
uterine wall <1/2 into the muscular layer, part of the tumor infiltrated the muscle layer in a MELF pattern, the cervical epithelium and stroma were involved and the cervical wall was infiltrated to a depth of <2/3 its thickness; iii) right parauterine tissue: MBT metastasis; iv) right pelvic lymph nodes: MBT metastasis (1/15).

The staging of the tumors was based on the American Joint Committee on Cancer (4) and the FIGO (5,6), as follows: i) MBT of ovary: pT3cN1M0, stage IIIC; and ii) UEC: T2N0M0, stage II (G1).

Postoperative treatment and follow-up. As MBT has a high degree of malignancy and metastasizes to parauterine tissues and pelvic lymph nodes, postoperative treatment is primarily focused on the MBT. The US 2021 National Comprehensive Cancer Network guidelines (7) recommend the use of paclitaxel + carboplatin or paclitaxel + carboplatin + bevacizumab for maintenance as the initial systemic treatment regimen for epithelial ovarian cancer stages II-IV. As bevacizumab may affect wound healing if applied less than two months after the operation, systemic treatment with paclitaxel + carboplatin regimen was initially adopted as an intravenous chemotherapeutic regimen. Follow-up by telephone was implemented with the patient for four months, the patient was treated at the hospital with chemotherapy twice and the patient is now undergoing radiotherapy and exhibiting disease-free survival for nearly one year.

Discussion

While synchronous primary cancers of the endometrium and ovary are common and endometrioid cancer may manifest in both areas (1,2), synchronous primary cancers of the UEC and ovarian MBT are relatively unusual (1,8). Furthermore, the coexistence of ovarian MBT and borderline mucinous cystadenoma combined with primary UEC is even rarer and no similar cases have been reported in the literature, to the best of our knowledge. Abnormal uterine bleeding (particularly post-menopausal uterine bleeding) is etiologically associated with endometrial cancer in 10-30% of cases (9), and the clinical manifestations of MBT are similar to those of other malignant ovarian tumors, including abdominal distension, abdominal pain, ovarian mass and abnormal vaginal bleeding (10). The present case was clinically uncovered due to abnormal uterine bleeding and increased vaginal discharge, likely caused by endometrial cancer with potential involvement of MBT. Although UEC may be readily further examined by hysteroscopy and diagnosed by fractional curettage, MBT has nonspecific features (mostly cystic-solid masses of the ovary) and the diagnosis of MBT thereby requires surgical excision and detailed pathologic observations (10).

It is difficult to distinguish synchronous primary cancers from metastatic cancers, particularly for synchronous primary carcinomas of the same histologic subtype. In 1985, Ulbright and Roth (11) delineated a set of pathologic criteria to distinguish metastatic disease from synchronous primary tumors and Scully et al (12) subsequently described more detailed clinicopathologic features to differentiate the metastatic origin between the ovary and the endometrium. If the pathologic findings of the tumors in different bodily regions favor the characteristics of independent primary cancers, a diagnosis of synchronous primary cancers may then be made. In the present case, the diagnosis was straightforward, since the histologic tumor types between the ovaries and endometrium were distinct.

Identification of histologic tumor types is principally dependent upon histomorphologic characteristics of the tumors. Endometrioid carcinoma is the most common histotype of endometrial carcinoma and its histologic characteristics are well known (13). Endometrioid carcinoma is characterized by glandular structures lined by columnar/cuboidal cells with round/ovoidal pseudostratified nuclei and a smooth luminal surface; nuclear atypia is most commonly of low grade; and such histologic features were duly noted in the present case.

Figure 4. Immunohistochemical findings of bilateral ovarian malignant Brenner tumor components. The tissue stained positive for (A) epithelial marker cytokeratin 7 and (B) urothelial marker uroplakin-III. Molecular genetics-related proteins that included (C) MDM2, (D) cyclin D1 and (E) EGFR also reacted positively. (F) The Ki67 hotspot index for the tumor cells was ~70% (scale bars, 100 µm).
Furthermore, altered differentiation such as mucinous, squamous or morular are common and are used as confirmatory features of the endometrioid histotype (13). It is worth noting that the present endometrioid carcinoma case exhibited the typical pattern of MELF infiltration, which refers to the patterns of microcapsulated, elongated and fragmented infiltration in endometrioid carcinoma; however, its incidence is low and it is frequently observed in certain low-grade endometrial carcinomas with deep myometrial infiltration (14). Investigators have ascertained that MELF infiltration is frequently accompanied by lymph node invasion (15); thus, if this pattern of infiltration is observed, special attention should be paid to determine whether there is vascular involvement and lymph node metastasis (LNM). Benign BT, borderline BT and MBT microscopically resemble urothelium and its neoplasms (16), and <5% of all BTs are malignant and microscopically characterized by destructive stromal invasion (17). In 1963, Idelson (18) postulated diagnostic criteria to diagnose an MBT, which stipulated the following: i) The tumor cells conform to Brenner's morphologic characteristics; ii) benign and borderline Brenner areas are present, preferably exhibiting transitional changes; iii) the possibility of pseudomucinous cystadenocarcinoma or teratoma may be excluded; and iv) metastasis of urothelial carcinoma may also be excluded. It may be suggested that stromal invasion by epithelial elements of MBT is demonstrated and this is a current prerequisite according to the most recent World Health Organization (WHO) classification (17,19).

While UEC frequently arises from atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia [its recognized precancerous lesion (20)], the histologic origin of ovarian BT remains controversial. The historically proposed origins of BT have included ovarian surface epithelium, mesonephric remnant, rete ovarii, mucinous tumor and teratomas (3). However, more recent evidence indicates that ovarian BT is derived from a Walthard cell nest (a type of urothelial metaplasia) that is usually found within the normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.

Immunohistochemically, low-grade UEC normally expresses ER, PR, vimentin, CK7 and CEA; whereas p16 and WT-1 were not expressed and P53 protein exhibited wild-type expression (22). In addition, since MLH1, PMS2, MSH2 and MSH6 were all positive in the present case, this indicated that the function of mismatch repair proteins was not lost and reflects immunophenotypes similar to those of normal ovaries and fallopian tubes (23). However, more recent evidence indicates that ovarian BT is derived from a Walthard cell nest (a type of urothelial metaplasia) that is usually found within the normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.

Immunohistochemically, low-grade UEC normally expresses ER, PR, vimentin, CK7 and CEA; whereas p16 and WT-1 were not expressed and P53 protein exhibited wild-type expression (22). In addition, since MLH1, PMS2, MSH2 and MSH6 were all positive in the present case, this indicated that the function of mismatch repair proteins was not lost and reflects immunophenotypes similar to those of normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.

Immunohistochemically, low-grade UEC normally expresses ER, PR, vimentin, CK7 and CEA; whereas p16 and WT-1 were not expressed and P53 protein exhibited wild-type expression (22). In addition, since MLH1, PMS2, MSH2 and MSH6 were all positive in the present case, this indicated that the function of mismatch repair proteins was not lost and reflects immunophenotypes similar to those of normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.

Immunohistochemically, low-grade UEC normally expresses ER, PR, vimentin, CK7 and CEA; whereas p16 and WT-1 were not expressed and P53 protein exhibited wild-type expression (22). In addition, since MLH1, PMS2, MSH2 and MSH6 were all positive in the present case, this indicated that the function of mismatch repair proteins was not lost and reflects immunophenotypes similar to those of normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.

Immunohistochemically, low-grade UEC normally expresses ER, PR, vimentin, CK7 and CEA; whereas p16 and WT-1 were not expressed and P53 protein exhibited wild-type expression (22). In addition, since MLH1, PMS2, MSH2 and MSH6 were all positive in the present case, this indicated that the function of mismatch repair proteins was not lost and reflects immunophenotypes similar to those of normal ovaries and fallopian tubes (21); with Walthard nests located in 50% of patients with BT and 59% of patients with mucinous tumor (3). The ultrastructural presence of tumor cell cilia also indicates that BT is more likely to originate from Walthard cell nests (16). Thus, in clinical practice, if the mucous component is observed in the tissue slice, it may augur a diagnosis of BT.
The primary differential diagnosis of low-grade endometrioid carcinoma is serous carcinoma; distinction between the two is important, as they differ in terms of prognosis and therapy (33). While patient features and tumor histology are useful in making a differential diagnosis, serous and low-grade endometrioid carcinomas may exhibit similar growth patterns, including glandular, papillary, micropapillary and solid forms; in addition, immunohistochemical staining (including that for p53 and p16) may be conducive to making this distinction (33). Loss of mismatch-repair proteins in cancer tissue or in Lynch syndrome-associated adenocarcinoma suggests EEC. In the 2020 classification from the WHO (34), increased emphasis is now put on The Cancer Genome Atlas molecular typing of endometrial cancer so as to predict prognosis rather than only its histologic type. When the histologic tumor type remains uncertain, application of Gilks' binary grading system may provide more useful prognostic information compared with FIGO grading (33). The primary differential diagnosis with respect to MBT is transitional cell carcinoma (TCC), and while they reflect similar morphologic features and immunohistochemical phenotypes, the two grading systems also possess numerous disparities. In a previous study, imaging and gross examination suggested that TCC lacked the common calcification of MBT and that MBT was more commonly expressed at stage I without extravesicular spread, while ~69% of ovarian TCC was diagnosed in the advanced stage (35). Microscopically, although TCC was not accompanied by benign BT or borderline BT components, it exhibited obvious malignant features. TCC usually has diffuse strong immunoreactivity for p16, Rb and p53, while MBT is negative. In BT, the expression of EGFR, RAS and CCND1 is concomitantly elevated with the increase in the degree of malignancy, but this phenomenon is lacking in TCC. There are also numerous differences in molecular changes; for instance, a p53 gene mutation is prominently observed in TCC (36).

Determining the appropriate treatment modality for patients diagnosed with synchronous primary endometrial and ovarian cancer depends upon the grade and stage of tumors in each topographic location (37). In the present study, surgery was first performed, followed by adjuvant treatment in the form of chemotherapy or radiotherapy according to tumor stage. If diagnosed as stage IA, no additional treatment was required after surgery; if diagnosed as IIIA or II, additional treatment was required (37). The final diagnosis of the present case was stage IIIC of MBT in the ovary and stage II of UEC, and therefore, radiotherapy was performed after chemotherapy. It was previously demonstrated that the use of a platinum-based chemotherapeutic agent plus paclitaxel post-operatively improved patient survival (38). In the present study, it was indicated that MDM2 amplification was associated with MBT and that MDM2 may therefore be selected in the future as a drug target for patients with MBT (39).

It has been reported that tumors with endometrioid histologic features at both sites have a favorable prognosis, while non-endometrioid tumor morphologies at both sites share a poor prognosis (2). In one study, the histopathologic type of the ovarian cancer component, stage of endometrial cancer and level of CA125 at diagnosis have been observed to have a great influence on the development of recurrence and survival of synchronous primary carcinomas of the endometrium and ovary (40). Therefore, it may be posited that MBT in ovaries is a primary determining factor of prognosis with respect to the present case. It is generally conjectured that the prognosis of MBT is favorable, with a five-year survival rate of MBT confined to the ovaries of 94.5%; however, the rate involving extravesicular tissues was determined to be 51.3% (19). It was also reported that in patients with extraterine metastasis, such as that to the dura mater, lung, peritoneum, omentum, skin and bone, the recurrence rate was 28% (19), and the average recurrence time for MBT was 11 months (41). LNM of MBT is not common and it is revealed in only 5.1% of patients, and when it does occur, lymphadenectomy exerts no effect on the improvement in the five-year survival rate of MBT (19). Although CA-125 is not specific and its concentration is not related to the malignant degree of a tumor, ~70% of patients with MBT have elevated CA-125 levels. Therefore, CA-125 remains the most important tumor marker for the post-treatment monitoring of disease recurrence (19,41).

Acknowledgements

Not applicable.

Funding

The Fund of the Women and Children's Hospital of Chongqing Medical University provided financial support (grant no. 2021YJMS01).

Availability of data and materials

All of the data generated in the present study are included in the figures and/or tables of this article.

Authors' contributions

YC and CZ conceived and designed the study and wrote the availability of data and materials. YC and CZ confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Written informed consent was obtained from the patient for publication of this case report and its accompanying images.

Competing interests

The authors declare that they have no competing interests.

References

1. Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD and Wright JD: Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget 9: 28757-28771, 2018.
2. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM and Lu KH: Synchronous primary cancers of the endometrium and ovary: A single institution review. Arch Gynecol Oncol 94: 456–462, 2004.

3. Seidman JD and Khedmati F: Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: A study of 120 tumors. Arch Pathol Lab Med 132: 1753-1760, 2008.

4. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenson DM, Compton CC, Hess KR, Sullivan DC, et al (eds): AJCC cancer staging manual. 8th edition. Springer, New York, NY, 2017.

5. Zeppernick F and Meinhold-Heerlein I: The new FIGO grading and genomic subcategories in clinical practice: Recommendations of the international society of gynaecological pathologists. Int J Gynecol Pathol 38 (Suppl 1): S64-S74, 2019.

6. Soslow RA, Tornos C, Park KJ, Malbica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCullage WG and Gilks CB: Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: Recommendations of the international society of gynaecological pathologists. Int J Gynecol Pathol 38: 191-216, 2019.

7. King L, Gogoi RP, Hummel C and Smith A: Malignant Brenner tumor from atrophic endometrium. Gynecol Oncol 137: 245-251, 2015.

8. Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, D'Alessandris N, Scaglione G, Fiorentino V, Raffone A, et al: Ovarian carcinoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19: 219-236, 2021.

9. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Berek J, Deschamps A, Dicker AP, Fader AN, Ferris RL, et al: Immunohistochemical separation from urothelial and other ovarian carcinomas. Hum Pathol 117: 42-50, 2021.

10. Mehi A, Ayhan A, Shih IeM, Seidman JD and Kurman RJ: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Pathol Lab Med 134: 584-590, 2020.

11. Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, D'Alessandris N, Scaglione G, Fiorentino V, Raffone A, et al: Ovarian carcinoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19: 219-236, 2021.

12. King L, Gogoi RP, Hummel C and Smith A: Malignant Brenner tumor from atrophic endometrium. Gynecol Oncol 137: 245-251, 2015.

13. Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, D'Alessandris N, Scaglione G, Fiorentino V, Raffone A, et al: Ovarian carcinoma, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19: 219-236, 2021.

14. Stewart CJ, Brennan BA, Leung YC and Little L: MELF pattern in endometrial cancer as a risk factor for lymph node metastasis. Arch Gynecol Obstet 285: 133-141, 2020.

15. Pavlakis K, Messini I, Vrekoussis T, Panoskaltsis T, Patsiou E, Diamanti‑Kandarakis E, Zwarthoff EC, Pijnenborg JM, van den Berg‑van Erp SH, Hummel C, et al: Malignant Brenner tumor associated with ovarian cyst-cyst presentation. Rom J Morphol Embryol 57 (Suppl 2): 893-898, 2016.

16. Kuhn E, Ayhan A, Shih IeM, Seidman JD and Kurman RJ: The pathogenesis of atypical proliferative Brenner tumor: An immunohistochemical and molecular genetic analysis. Mod Pathol 27: 1223-1237, 2014.

17. Kondi‑Pafiti A, Kairi‑Vassilatou E, Iavazzo Ch, Vouza E, Krawczyk D, Vrakas A, Papadopoulou A, Vaziri‑Moghadam G, Vrentzidou A, et al: Malignant Brenner tumours presenting as a acute appendicitis. Ann Anat 194: 335-341, 2012.

18. Idelson MG: Malignancy in Brenner tumors of the ovary, with comments on histogenesis and possible estrogen production. Arch Pathol Lab Med 143: 1278-1280, 2019.

19. Kuhn E, Ayhan A, Shih IeM, Seidman JD and Kurman RJ: The pathogenesis of atypical proliferative Brenner tumor: An immunohistochemical and molecular genetic analysis. Mod Pathol 27: 1223-1237, 2014.

20. Wang L, Allison D and Shukla PS: Amplification of MDM2 and loss of p16 expression: Do they have a role in malignant transformation of ovarian Brenner tumor? Am J Clin Pathol 154: 133-141, 2020.

21. Albu DF, Albu CC, Gogănașu AM, Albu ŞD, Mogoanăt L, Edu A, DiŢescu D and Jadova CC: Borderline Brenner tumor associated with ovarian cyst-cyst presentation. Rom J Morphol Embryol 57 (Suppl 2): 893-898, 2016.

22. Seidman JD, Khedmati F and Zoundi Y: The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Pathol Lab Med 134: 584-590, 2020.

23. Kuhn E, Ayhan A, Shih IeM, Seidman JD and Kurman RJ: The pathogenesis of atypical proliferative Brenner tumor: An immunohistochemical and molecular genetic analysis. Mod Pathol 27: 1223-1237, 2014.

24. King L, Gogoi RP, Hummel C and Smith A: Malignant Brenner tumor from atrophic endometrium. Gynecol Oncol 137: 245-251, 2015.